
{"id":31,"date":"2017-07-25T14:31:17","date_gmt":"2017-07-25T18:31:17","guid":{"rendered":"http:\/\/pages.charlotte.edu\/pinku-mukherjee\/?page_id=31"},"modified":"2017-07-25T14:31:17","modified_gmt":"2017-07-25T18:31:17","slug":"2000-2006","status":"publish","type":"page","link":"https:\/\/pages.charlotte.edu\/pinku-mukherjee\/2000-2006\/","title":{"rendered":"2000 &#8211; 2006"},"content":{"rendered":"<p><strong>Mukherjee, P.,<\/strong> Ginardi, A.R., Madsen, C.S., Sterner, C.J., Adriance, M.C., and Gendler, S.J. (2000) Mice with spontaneous pancreatic cancer naturally develop MUC1-specific CTLs that eradicate tumors when adoptively transferred. <em>Journal of Immunology<\/em> 165: 3451-3460.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Mukherjee, P.,<\/strong> Ginardi, A.R., Tinder, T.L., Sterner, C.J. and Gendler S.J. (2000) MUC1-specific CTLs eradicate tumors when adoptively transferred <em>in vivo<\/em>. <em>Clinical Cancer Research <\/em>7: 848 \u2013 855<em>.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>Gendler, S.J., and <strong>Mukherjee, P<\/strong>. (2001) Spontaneous Adenocarcinoma Mouse Models for Immunotherapy<em>. Trends in Molecular Medicine, <\/em>7: 471 &#8211; 475.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p>McConnell, E.J., Pathangey, L.B., Madsen, C.S., Gendler, S.J., and <strong>Mukherjee, P.<\/strong> (2002) DC-Tumor Cell Fusion and SEB Treatment in a Pancreatic Tumor Model. <em>J. Surgical Research<\/em> 107: 196 &#8211; 202.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Mukherjee, P.,<\/strong> Madsen, C.S., Ginardi, A.R., Tinder, T.L., Jacobs, F., Parker, J., Agrawal, B., Longenecker, B.M. and Gendler, S.J. (2003) MUC1-specific immunotherapy in a mouse model of spontaneous breast cancer. <em>J. Immunother<\/em> 26:47-62.<\/p>\n<p>&nbsp;<\/p>\n<p>Xia J, Tanaka Y, Koido S, Liu C, <strong>Mukherjee P<\/strong>, Gendler SJ and Gong J (2003) Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic\/tumor fusion cells. <em>J Immunol<\/em> 170:1980-1986.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Mukherjee P<\/strong>, Ginardi AR, Madsen CS, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, and Gendler SJ (2003) MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. <em>Glycoconjugate J<\/em> 18:931-942.<\/p>\n<p>&nbsp;<\/p>\n<p>Chen, D. Xia, J., Tanaka, Y., Chen, H. Koido, S., Werner, O., <strong>Mukherjee, P.,<\/strong> Gendler, S.J., Kufe, D. and Gong, J. (2003) Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. <em>Immunology <\/em>109:300-307.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p>Pockaj, B.A., Basu, G.D., Pathangey, L.B., Gray, R.J., Hernandez, J.L., Gendler, S.J. and<strong> Mukherjee, P. <\/strong>(2004) Reduced T cell function is related to COX-2 over-expression and PGE<sub>2<\/sub> secretion in patients with breast cancer. <em>Ann Surg Oncol<\/em> 11:328-339.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Mukherjee, P.,<\/strong> Tinder, T.L., Basu, G.D., Pathangey, L.B., Chen, L. and Gendler, S.J. (2004) Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model. <em>Breast Disease <\/em>20:53-63<em>.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>Gargi D. Basu, Latha B. Pathangey, Teresa L. Tinder, Michelle LaGioia, Sandra J. Gendler, and <strong>Pinku Mukherjee<\/strong> (2004) COX-2 inhibitor induces apoptosis in breast cancer cells in an <em>in vivo<\/em> model of spontaneous metastatic breast cancer. <em>Mol Cancer Res <\/em>2:632-642 <strong>(Cover) (American Association for Cancer Research\u00a0 Press Release)<\/strong>.<\/p>\n<p>&nbsp;<\/p>\n<ol start=\"99\">\n<li><strong> Mukherjee,<\/strong> T. L. Tinder, G. D. Basu, and S. J. Gendler (2005) MUC1 modulates human T lymphoma cell proliferation. <em>J Leukoc Biol <\/em>77:90-99.<\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p>Gargi D. Basu, Latha B. Pathangey, Sandra J. Gendler, and <strong>Pinku Mukherjee <\/strong>(2005) The cyclooxygenase-2 inhibitor, celecoxib, inhibits growth and micro-vascular channels in human breast cancer cells. <em>Breast Cancer Research<\/em>, 7:422-435 <strong>(Breast Cancer Net News Release)<\/strong>.<\/p>\n<p>&nbsp;<\/p>\n<p>Theodore H. Lindsay, Beth M. Jonas, Molly A. Sevcik, Kazufumi Kubota, Kyle G. Halvorson, Joseph R. Ghilardi, Micheal A. Kuskowski, Edward B. Stelow, <strong>Pinku Mukherjee,<\/strong> Sandra J. Gendler, Gilbert Y. Wong, Patrick W. Mantyh (2005) Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. <em>Pain<\/em>, 119:233-246 <strong>(Cover)<\/strong>.<\/p>\n<p>&nbsp;<\/p>\n<p>Gargi D. Basu, Teresa L. Tinder, Bradley, J.M., Tu, T., Hattrup, C.L., Pockaj, B.A., and <strong>Pinku Mukherjee. <\/strong>(2006). Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine. <em>Journal of Immunology, <\/em>177:2391-2402.<\/p>\n<p>&nbsp;<\/p>\n<p>Thompson, E.J., Shanmugam, K., Hattrup, C.L., Kotlarczyk, K.L., Gutierrez, A., Bradley, J.M., <strong>Mukherjee, P.<\/strong> and Gendler, S.J. (2006). Tyrosines in the MUC1 cytoplasmic tail modulate transcription via the ERK1\/2 and NF-\u03baB pathways. <em>Molecular Cancer Research, <\/em>4:489-497.<\/p>\n<p>&nbsp;<\/p>\n<p>Nate Koewler, Molly A. Sevcik, Beth M. Jonas, Theodore H. Lindsay, Kyle G. Halvorson, Joseph R. Ghilardi, <strong>Pinku Mukherjee<\/strong>, and Patrick W. Mantyh (2006). Endogenous Opiods inhibit early stage pancreatic pain in a mouse model of pancreatic cancer. <em>Gastroenterology, <\/em>131: 900-910.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mukherjee, P., Ginardi, A.R., Madsen, C.S., Sterner, C.J., Adriance, M.C., and Gendler, S.J. (2000) Mice with spontaneous pancreatic cancer naturally develop MUC1-specific CTLs that eradicate tumors when adoptively transferred. Journal of Immunology 165: 3451-3460. &nbsp; Mukherjee, P., Ginardi, A.R., Tinder, T.L., Sterner, C.J. and Gendler S.J. (2000) MUC1-specific CTLs eradicate tumors when adoptively transferred in [&hellip;]<\/p>\n","protected":false},"author":1132,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"class_list":["post-31","page","type-page","status-publish","hentry"],"jetpack_shortlink":"https:\/\/wp.me\/P2mjag-v","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/pages.charlotte.edu\/pinku-mukherjee\/wp-json\/wp\/v2\/pages\/31","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pages.charlotte.edu\/pinku-mukherjee\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pages.charlotte.edu\/pinku-mukherjee\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pages.charlotte.edu\/pinku-mukherjee\/wp-json\/wp\/v2\/users\/1132"}],"replies":[{"embeddable":true,"href":"https:\/\/pages.charlotte.edu\/pinku-mukherjee\/wp-json\/wp\/v2\/comments?post=31"}],"version-history":[{"count":1,"href":"https:\/\/pages.charlotte.edu\/pinku-mukherjee\/wp-json\/wp\/v2\/pages\/31\/revisions"}],"predecessor-version":[{"id":32,"href":"https:\/\/pages.charlotte.edu\/pinku-mukherjee\/wp-json\/wp\/v2\/pages\/31\/revisions\/32"}],"wp:attachment":[{"href":"https:\/\/pages.charlotte.edu\/pinku-mukherjee\/wp-json\/wp\/v2\/media?parent=31"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}